On the mechanism of autoinhibition of the RhoA-specific nucleotide exchange factor PDZRhoGEF
© Zheng et al; licensee BioMed Central Ltd. 2009
Received: 13 February 2009
Accepted: 21 May 2009
Published: 21 May 2009
The Dbl-family of guanine nucleotide exchange factors (GEFs) activate the cytosolic GTPases of the Rho family by enhancing the rate of exchange of GTP for GDP on the cognate GTPase. This catalytic activity resides in the DH (Dbl-homology) domain, but typically GEFs are multidomain proteins containing other modules. It is believed that GEFs are autoinhibited in the cytosol due to supramodular architecture, and become activated in diverse signaling pathways through conformational change and exposure of the DH domain, as the protein is translocated to the membrane. A small family of RhoA-specific GEFs, containing the RGSL (regulators of G-protein signaling-like) domain, act as effectors of select GPCRs via Gα12/13, although the molecular mechanism by which this pathway operates is not known. These GEFs include p115, LARG and PDZRhoGEF (PRG).
Here we show that the autoinhibition of PRG is caused largely by an interaction of a short negatively charged sequence motif, immediately upstream of the DH-domain and including residues Asp706, Glu708, Glu710 and Asp712, with a patch on the catalytic surface of the DH-domain including Arg867 and Arg868. In the absence of both PDZ and RGSL domains, the DH-PH tandem with additional 21 residues upstream, is 50% autoinhibited. However, within the full-length protein, the PDZ and/or RGSL domains significantly restore autoinhibition.
Our results suggest a mechanism for autoinhibition of RGSL family of GEFs, in which the RGSL domain and a unique sequence motif upstream of the DH domain, act cooperatively to reduce the ability of the DH domain to bind the nucleotide free RhoA. The activation mechanism is likely to involve two independent steps, i.e. displacement of the RGSL domain and conformational change involving the autoinhibitory sequence motif containing several negatively charged residues.
Rho (R as-h omology) cytosolic GTPases function as molecular switches that, in the GTP-bound form, interact with a multitude of effectors that exert control over cytoskeletal elements, gene transcription, and other biological phenomena [1–3]. Spatial and temporal control over these GTPases is exercised by GEFs (guanine nucleotide exchange factors), which load up GTP and activate cognate GTPases, and by GAPs (GTPase activating proteins) which are required by the GTPase for efficient hydrolysis of GTP to GDP [4, 5]. Most of Rho GEFs belong to the Dbl-homology family of large, multidomain proteins . There are approximately 70 of these proteins in the human proteome, some highly specific and some activating indiscriminately two or more different Rho GTPases [5, 7]. The catalytic step is executed by the Dbl-homology (DH) domain, often assisted by a pleckstrin-homology (PH) domain, which is invariably located immediately downstream of the DH domain [6, 7]. The DH domain, either alone or synergistically with the PH-domain, binds the cognate GTPase in its nucleotide-free form. Upon release, the GTPase forms a biologically active complex with the more abundant GTP nucleotide . The GEFs are thought to be inactive in their nascent form due to a 'folded', or 'closed' conformation, in which specific domains or motifs outside the DH-PH tandem bind to those surfaces on the DH domain which are involved in the binding of the GTPase . The activation of specific GEFs requires extra- or intracellular stimuli that directly or indirectly induce conformational changes in GEFs leading to release of autoinhibition and expression of full catalytic potential. While this paradigm may be generally conserved, details vary depending on the architecture of a particular GEF.
Recently, structural studies elucidated the mechanism of autoinhibition in several Dbl-homology GEFs. The proto-oncogene product Vav, which activates Rac1, is autoinhibited by an N-terminal, helical extension of the DH-domain which lies in the GTPase interaction site. This autoinhibition is relieved by Src-mediated phosphorylation of Tyr174, which is in the center of the autoinhibitory helix . In Asef, a Rac-specific exchange factor, the activity of its DH domain is suppressed through an intramolecular interaction with an SH3 domain, found immediately upstream of the DH module [10, 11]. It is possible that a similar mechanism is also in operation in other GEFs that show a similar architecture of SH3-DH-PH modules. In contrast, the Rho-specific p63RhoGEF contains no identifiable domains other than the DH-PH tandem, and the autoinhibition is mediated by a conserved, α-helical C-terminal extension of the PH domain . Analogous extensions are found in Trio and Kalirin, and the autoinhibition mode of these GEFs may be very similar to that of p63RhoGEF .
A family of three RhoA-specific GEFs act downstream of the Gα12/13-coupled receptors (GPCRs). They are: p115RhoGEF , PDZRhoGEF, henceforth referred to as PRG , and LARG [15, 16]. This family is distinguished by the presence of the RGSL (regulator of G-protein signaling-like) domain, upstream of the DH-PH tandem. Further, both PRG and LARG contain additional N-terminal extensions which include a PDZ (P SD-95, Disc-large, ZO1) domain. Finally, downstream of the DH-PH tandem, all three GEFs contain a ~400 residue long, largely unstructured region which include a coiled-coil fragment that mediates homo- and heterodimerization .
There is considerable evidence that Gα12/13 activates the RGSL-family of Dbl-homology GEFs via direct interaction with the RGSL domain. Crystal structures of these domains from both p115 and PRG have been determined [18, 19], and additionally the structure of the complex of the p115 RGSL domain with the Gα12/i3 chimera elucidated the nature of the interaction of both proteins . However, this did not explain how RGSL-domain containing GEFs are activated. Further, it appears that mere physical interaction does not necessarily result in up-regulation of GEF activity. For example, the RGSL domain of p115 has been shown to bind to both Gα12 and Gα13, but only Gα13, stimulates the GEF activity for p115RhoGEF and non-phosphorylated LARG . Gα12 will stimulate LARG when the latter is phosphorylated, although it is not known why . An excellent review of the interactions of RGSL-family GEFs with G proteins was published recently .
There is also evidence that the PDZ domain may be important for the activation of LARG and PRG. Typically, these relatively small domains are expected to play a role in targeting proteins to large membrane-associated protein complexes [24–26]. However, there is evidence that interactions mediated by the PDZ domains of both LARG and PRG may also activate their nucleotide exchange function. For example, plexin-B family of receptors bind the PDZ domains of both LARG and PRG leading to RhoA activation [27–29]. It has also been reported that the lysophosphatidic acid receptors, LPA1 and LPA2, bind the PDZ domain of PRG, and that this interaction leads to activation of the RhoA pathway in HEK293 cells . The same PDZ domain was also shown to interact with the microtubule associated protein 1 (MAP1) light chain and this interaction modulated the GEF activity . Finally, the PDZ domain of LARG was shown to bind to CD44 (major hyaluronan receptor), also upregulating RhoA .
Since the mechanism of autoinhibition of the RGSL-family of GEFs has not been elucidated, it is difficult to speculate how the interactions mediated by RGSL and PDZ domains may lead to activation of LARG or PRG, and if they act synergistically or through alternative and independent mechanisms. In the present study we investigated the question of the molecular basis of autoinhibition of the RGSL family of GEFs. We find that the recombinant fragment encompassing residues 37–1081 and including all four key domains (PDZ, RGSL, DH and PH) of PRG is indeed autoinhibited, and shows only ~15% of the intrinsic catalytic activity of the isolated DH-PH tandem. Unexpectedly, the removal of the PDZ domain, or of a fragment containing both the PDZ and RGSL domains, has limited effect on the catalytic rates, which are 18% and 35% of that of the isolated DH-PH tandem, respectively. We identify an autoinhibitory element within the sequence immediately upstream of the DH-PH tandem, and we trace the autoinhibition of PRG primarily to an interaction between a negatively charged sequence motif, including Asp706, Glu708, Glu710 and Asp712, and a positive patch on the DH domain that is involved in the recognition and binding of RhoA. Our results reveal a complex autoinhibitory mechanism and suggest the possibility that in addition to relief of autoinhibition through protein-protein interactions, actual up-regulation of the intrinsic nucleotide exchange activity of GEFs by interacting partners may constitute a hitherto unrecognized regulatory mechanism.
Results and discussion
Identification of an autoinhibitory element in the RGSL-DH linker region
Unexpectedly, the removal of the RGSL domain (PRG496–1081) did not relieve autoinhibition, and the resulting protein showed only 33-fold enhancement in nucleotide exchange on RhoA, i.e. ~65% autoinhibition. Thus, we concluded that key elements responsible for autoinhibition reside within the 200 amino acid linker sequence between the RGSL and DH domains. Secondary structure prediction suggests that the linker sequence has propensity to form localized helical structures, although more than 50% of the sequence is predicted to harbor unstructured regions (not shown). We were able to express the linker region (residues 476–711) and a CD (circular dichroism) spectrum (not shown) was consistent with a random coil structure. Given that the sequence gave no clue as to the identity of the functionally important fragment, we expressed additional, progressively shorter constructs, i.e. PRG524–1081, PRG630–1081, PRG672–1081 and PRG691–1081. All retained a significant level of autoinhibition. We then measured the nucleotide exchange rate on RhoA in the presence of both the isolated DH-PH tandem (i.e. PRG712–1081), and the isolated fragment containing the RGSL domain with the C-terminal linker (i.e. PRG277–711), or just the recombinant linker (i.e. PRG496–711). Both experiments gave results identical to those obtained for the DH-PH tandem alone, indicating that the neither the RGSL domain, nor the RGSL domain with its C-terminal extension are capable of interacting with the DH-PH tandem in the absence of a covalent link.
Chemical shift assignment of DH-PH
When we compared the spectra of the DH-PH tandem with the spectra of the isolated domains, we found that a vast majority of signals were only slightly shifted, allowing us to use the assignment for the isolated domains to directly assign the chemical shifts for the tandem. In addition, we used the sequential connectivities derived from HNCA and 1H-15N HSQC-NOESY experiments measured for the tandem. Overall, we assigned 72% of backbone amides in the DH-PH tandem: 84% for the DH domain but only 55% for the PH domain, due to resonance broadening.
Interactions of the autoinhibitory element with the DH domain and with RhoA
In order to determine the position of the linker relative to the DH domain, we mapped residues with affected chemical shifts onto the crystal structure of the complex. Interestingly, we found that the linker could adopt a conformation, in which it can interact with RhoA. To test this we measured spectra of 2H,15N-labeled RhoA in complex with unlabeled DH-PH and PRG712–1081. In both cases we observed formation of tight complexes, as evidenced by slow exchange on NMR timescale. Further, we also found that the presence of the linker affects chemical shifts of several amides within RhoA (Fig. 4D). However, the magnitude of the chemical shift changes is smaller than that for the DH domain. Therefore, the interaction of the linker with RhoA is less intimate than that with the DH domain. Due to the lack of the chemical shift assignments of RhoA in the complex, the detailed analysis of perturbed residues was not possible.
The nature of the interdomain interactions
The observation that Arg867 and Arg868 in the DH domain may be affected by interaction with the linker, prompted us to look at two negatively charged clusters in the linker: one made up of Glu698, Asp699 and Asp700, and the second which includes Asp706, Glu708, Glu710 and Asp712. These clusters are reminiscent of the so-called acidic region of Vav1, harboring the autoinhibitory helix . A triple mutation E698A, D699A, D700A had little effect on the catalytic rate, as did truncation resulting in the PRG701–1081 construct (see above). In contrast, a charge reversal mutant E698R, D699R, D700R (hereafter referred to as PRG3R) showed catalytic activity slightly above that of the isolated DH-PH tandem, suggesting complete relief of autoinhibition. Further, a charge reversal quadruple mutant of the second cluster D706R, E708R, E710R, D712R (denoted PRG4R) showed a significant increase in catalytic activity, 3.3 fold over the isolated DH-PH tandem. A possible explanation is that the kinetics of RhoA binding by the DH-PH tandem are altered, i.e. the off and on rates could be elevated, with no concomitant change in binding affinity for the nucleotide free RhoA, leading to higher turnover of nucleotide free RhoA to RhoA•GTP.
To better understand the role of individual amino acids, we generated four single-site mutants of the PRG712–1081 construct, i.e. D706R, E708R, E710R and D712R (see above). The E710R mutant shows significant autoinhibition (it is actually less active in the in vitro assay than PRG701–1081), but each of the remaining mutants exhibits catalytic activity comparable to the isolated DH-PH tandem. It is therefore possible that the observed enhanced catalytic potential of the PRG4R is due to additive effects of individual mutations. Interestingly, within the context of the intact four-domain construct (i.e. PRG37–1081) most of the autoinhibition is effectively restored, indicating that both the PDZ and RGSL domains play an important role.
The next step was to evaluate the effect of the mutations in the linker on the direct interaction of the PRG712–1081 with RhoA. We measured 1H-15N TROSY-HSQC spectra of 15N-labeled RhoA in complexes with each of the two mutants, i.e. PRG3R, and PRG4R. The spectrum of RhoA in the presence of PRG3R is essentially identical to that of RhoA in the presence of the wild-type PRG672–1081 indicating no significant effect of the mutations in the linker on the interaction with RhoA (data not shown). However, noticeable changes are observed for RhoA in the presence of the PRG4R with over a dozen resonances shifted by more than 25 Hz (Fig. 5C). As inferred from the NMR analysis, the linker of the PRG4R mutant appears to interact with negatively charged surfaces of RhoA (Fig. 5D). Reversing the charge of acidic residues within the linker appears to have a pronounced effect on the kinetics of DH-PH/RhoA interaction and ultimately, the rate of nucleotide exchange.
The role of PDZ-RGSL domains
To evaluate the impact of the mutations in the linker region on the autoinhibited core fragment of PRG containing all four functional domains, we carried out the nucleotide exchange assay for PRG37–1081 with the D706R, E708R, E710R and D712R mutations. The rate of exchange was increased from ~20, in the wild-type PRG37–1081, to 43, i.e. only two-fold. Interestingly, this is equivalent to eliminating the PDZ and RGSL domains from wild-type PRG37–1081. This result shows that autoinhibition in the wild-type, full-length protein is an additive effect of a number of different interactions.
Functional assays are consistent with the in vitro model
The model of autoinhibition
Based on these results, we suggest that the activation of PRG, and probably also of the two other remaining members of this family of GEFs, i.e. LARG and p115, proceeds by a multistep mechanism. The primary autoinhibitory element resides upstream of the DH-PH tandem, but may not be accessible due to secondary interactions with RGSL and/or PDZ domains. This is why a conformational change involving the latter domains is essential, but not sufficient for full GEF activation. In agreement with this model, activated, GTP-bound Gα13 can bind directly to a fragment containing both the linker and DH-PH tandem of the p115 GEF, but without concomitant activation of the nucleotide exchange activity . Thus, both the RGSL domain and the 'activation box' may act synergistically. Also, activation of GEF activity can be partially uncoupled from binding of Gα13 to the RGSL domain in p115 GEF: point mutations in the latter that reduce affinity for Gα13 have no effect on the activation of nucleotide exchange of p115 GEF . Analogous mutants do not affect translocation of p115 GEF to particulate fractions in the presence of Gα13, suggesting that translocation of p115 GEF is due to complex mechanisms involving elements other than the RGSL domain .
We here propose that in the closed, autoinhibited form, the RGSL domain interacts with both the RGSL-DH linker and the DH domain, or perhaps only with the linker, which serves as the direct inhibitory element (Fig. 7). When the RGSL domain binds to Gα12/13, the inhibitory element remains in place, but becomes exposed and accessible to secondary interactions which in consequence remove the linker from the functional DH surfaces. The dramatic effect of the charge reversal mutant also suggests that electrostatic interactions could play a major role, not only in relieving the autoinhibition, but also in positive regulation of the kinetics of RhoA binding and nucleotide exchange. It is typically assumed that the intrinsic catalytic properties of the DH domain, or more commonly the DH-PH tandem, reflect the maximum theoretical nucleotide exchange rate of the respective GEF. However, this is not always true. The isolated DH domain of Vav enhances the nucleotide exchange rate on Rac1 73-fold, but the addition of the PH-CRD fragment produces a further 13-fold enhancement . Thus, it is possible that an activating interaction, e.g. involving Gα subunits, may not only relieve the autoinhibition, but also directly up-regulate the GEF activity. In that context, we note that the human Gα12 and Gα13 subunits differ with regard to their pI values, i,e. 9.8 and 8.2, respectively, and the positively charged surfaces could be important in the interaction with the DH/RhoA complex.
Finally, we note that the proposed mechanism might be relevant to all three GEFs of the RGSL-family. The amino acid sequences of both LARG and p115 show similar negatively charged patches in nearly identical locations: LARG contains a Glu-Asp-Glu tripeptide, while p115 GEF has an Asp-Glu-Gly-Glu motif (Additional File 1: Figure S2). Further work, underway in our laboratories, will hopefully establish the details of these pathways.
Protein Expression and Purification
Full-length and truncated versions of human PDZRhoGEF were PCR-amplified and subcloned into pDEST15 (Invitrogene) vector containing a glutathione S-transferase (GST) tag at the N-terminus, an rTEV protease site between GST and the insert, and a non-cleavable His8 tag at the C terminus. All constructs were verified by direct sequencing prior to protein expression. The proteins were expressed in the E. coli strain BL21 (DE3) RIPL (Strategene). Cell cultures were grown at 37°C in TB/ampicillin (100 μg/ml) and chloramphenicol (34 μg/ml), and induced with 1 mM isopropyl β-D-thiogalactopyranoside (IPTG) overnight at 18°C. Cell pellets were resuspended in 50 mM Tris pH 7.8, 300 mM NaCl, 0.5 mM EDTA, 1 mM dithiothreitol (DTT) (Buffer A), lysed using Sonifier 450 (VWR), and clarified by centrifugation at 40,000 × g for 45 min at 4°C. Supernatant was loaded on a glutathione-Sepharose 4B column (Pharmacia), pre-equilibrated with Buffer A. Protein was bound to the resin by gently rocking the column at 4°C for 1 hour and eluted with 20 mM glutathione in 50 mM Tris, pH 8.0, 50 mM NaCl, 0.5 mM EDTA, 1 mM DTT (Buffer B). Fractions containing pure fusion protein were pooled, digested overnight with rTEV protease in the same buffer and then dialyzed against Buffer B to remove glutathione. After rTEV cleavage, the protein solution was loaded again on glutathione-Sepharose 4B column and rocked for 1 hour to remove GST and the uncut fusion protein. Flow-through was collected and diluted with 50 mM Tris pH 8.0, 150 mM NaCl (Buffer C). The solution was then loaded onto Ni-NTA column pre-equilibrated with buffer C and eluted with 200 mM imidazole in Buffer C. Fractions containing pure protein were pooled and dialyzed against 20 mM Tris pH 7.5, 150 mM NaCl, 1 mM DTT. Pure protein was concentrated and stored at -80°C for the fluorescence assay.
Proteins labeled with stable isotopes (2H, 13C, 15N) were expressed in minimal media with (15NH4)2SO4 as sole source of nitrogen and 13C- or 2H,13C-glucose as a source of carbon. The media were enhanced by the addition of labeled BioExpress (Cambridge Isotope Labs.). Four types of labeling scheme were used: 15N, 13C 15N, 2H 15N and 2H 13C 15N.
The expression and purification of human RhoAF25N (residues 1–181) was carried out as described previously .
Guanine Nucleotide Exchange Assay
Fluorescence spectroscopy analysis of N-methylanthraniloyl (mant)-GTP incorporation into RhoA was carried out using a FluoroMax-3 (Jobin Yvon Inc.) spectrofluorimeter. The exchange reaction was carried out at 22°C for 5 min in a 1.5 ml Eppendorf tube containing 1 μM GDP-preloaded RhoA and 0.5 μM mant-GTP in 20 mM Tris-HCl, (pH 7.5), 50 mM NaCl, 5 mM MgCl2 and 1 mM DTT. After equilibration, assayed proteins were added at 0.1 μM concentration and increases in mant-GTP fluorescence was monitored (λex = 356 nm, λem = 450 nm). The control experiment, in the absence of other proteins, reflects intrinsic exchange activity of RhoA, measured after equivalent equilibration time. Each exchange experiment was carried out three times independently. The initial rates of guanine nucleotide exchange were determined by regression analysis. The average variation among measured rate did not exceed 10%. Fold stimulation values were calculated as the ratio of the initial exchange rate of DH-PH-stimulated reaction to the intrinsic rate of exchange for the wild type RhoA.
Optimization of DH-PH samples for NMR experiments
In order to optimize both the stability of protein samples and the sensitivity of NMR experiments, we screened a large number of different buffers. We prepared 0.5 mM solution of DH-PH in several buffers with varied salt concentrations and kept the samples at 4 – 35°C with periodic monitoring of the concentration and the level of sample degradation using SDS-PAGE. We found the best solubility and stability of DH-PH samples in 50 mM TRIS buffer, pH 7.5 and 150 mM NaCl. However, such conditions do not provide optimal sensitivity for cryogenic probes due to high salt concentration . Therefore, to achieve the highest possible sensitivity of NMR experiments we tested several salt-free buffers and found a mixture of 200 mM MOPS/TRIS, pH 7.5, to be optimal. In such conditions DH-PH can remain in solution at a concentration above 0.3 mM for over a week at 25°C. Higher temperature, ~30°C, reduces the lifetime of the sample to approximately 3–4 days.
Because backbone assignment of perdeuterated proteins depends on efficient back-exchange of amide protons, we dissolved 15N-labeled DH-PH in D2O based buffer and monitored H/D exchange using the HSQC spectra. We observed complete exchange of amide protons over one week.
Chemical shift assignment
To assign the backbone amide chemical resonances of isolated DH and PH domains, we used standard triple resonance experiments (HNCO, HNCA, HN(CO)CA, HNCACB, CBCA(CO)NH and 3D 15N-edited NOESY with 200 ms mixing time). The spectra for 0.3 mM 2H,13C,15N-labeled DH domain in 200 mM MOPS/TRIS buffer, pH 7.5, and 2 mM DTT were collected using Varian Inova 600 MHz at 25°C. The spectra for 13C,15N-labelled PH domain were recorded using Varian Inova 500 MHz for 0.5 – 0.7 mM protein concentrations in 600 mM NaCl, 50 mM TRIS pH 7.0 and 2 mM DTT buffer at 25°C.
To assign the resonances in the intact DH-PH tandem, we used 2H,13C,15N labeled protein at 0.3–0.4 mM concentration in 200 mM MOPS/TRIS buffer at pH 7.5 and 2 mM DTT. The NMR spectra were collected at 30°C using Varian Inova 800 MHz spectrometer equipped with cryogenic probe. The following TROSY-based experiments were conducted: TROSY-HNCA, TROSY-HNCO, 3D 15N-edited TROSY-NOESY with 250 ms mixing time.
Chemical shift perturbation experiments
In order to analyze chemical shift perturbations we measured series of experiments using Varian Inova 900 MHz, Varian Inova 600 MHz and Bruker Avance 600 MHz spectrometers equipped with cryogenic probes. Samples for NMR contained 0.2 to 0.3 mM protein concentrations in 200 mM MOPS/TRIS buffer, pH 7.5 with 1 mM DTT. All of the 1H-15N TROSY-HSQC spectra were collected at 25°C.
Tissue Preparation and Force Measurements
Rabbits were anesthetized and killed with isoflurane. Small strips (100–150 μm thick, 150–200 μm wide, and 2–3 mm long) of rabbit pulmonary artery were dissected and freed from connective tissue. Single strips were tied with monofilament silk to the fine tips of two tungsten needles, one of which was connected to a force transducer and mounted in a well on a bubble plate, as described previously . After measuring contractions induced by high 154 mM K+, the strips were incubated at room temperature (21–22°C) in Ca2+ free relaxing solution (G1) containing 4.5 mM MgATP and 1 mM EGTA for several minutes and permeabilized with 75 uM β-escin for 25 min. This permeabilization protocol permits penetration of molecules up to 150 kDa . To deplete the sarcoplasmic reticulum of calcium . and inhibit NO-synthase activity, every strip was also treated with 10 μM A23187 (Calbiochem) and 10 μM L-NAME (Sigma) (for additional 10 min in the G1 solution. Buffer in protein samples of wild type and 4R mutant PRG core fragment (PRG37–1081) was exchanged against pCa 6.7, 1 μM calmodulin and 2 μM GTP. Samples of ~10–15 μM of recombinant protein were used to stimulate the force responses.
The Rhotekin assay
The cDNA of full-length wild-type PDZ-RhoGEF, as well as 3R and 4R mutants and the isolated DH-PH tandem were PCR amplified with flanking restriction sites and introduced into p3XFLAG-myc-CMV-24 mammalian expression vector (Sigma-Aldrich, St. Louis MO). NIH 3T3 cells were cultured on a 10 cm culture plate in Dulbecco's Modified Eagle Medium (DMEM; Invitrogen-Gibco) supplemented with 10% fetal bovine serum (FBS; Invitrogen-Gibco) at 37°C in 5% CO2. The plasmids for the ectopic expression with N-terminal 3XFLAG and C-terminal myc-tag, and coding sequences for the full-length wild-type, 3R or 4R mutant PDZ-RhoGEF or the DH-PD tandem were transfected into cells using Lipofectamine 2000 (Invitrogen) following manufacture's standard protocol. The cells were treated for transfection, cultured overnight, treated for transfection for the second time and cultured in DMEM without FBS, changed 8 hours after the second transfection, overnight. RhoA activation was determined by precipitation of active GTP-bound RhoA (RhoA•GTP) with a glutathione S-transferase (GST)-fusion protein of the Rho-binding domain (RBD) of the Rho effector rhotekin as previously described . Briefly, the cells on a 10 cm plate were lysed in 500 μl of ice cold lysis buffer (25 mM HEPES, pH 7.5; 150 mM NaCl; 1% NP-40; 10 mM MgCl2; 1 mM EDTA; 6% Glycerol; 1% Protease inhibitor cocktail (Sigma-Aldrich, St. Louis MO)), and cleared by centrifugation at 14,000 g for 10 minutes at 4°C. Ectopic expression of full-length wild-type, 3R and 4R mutant PDZ-RhoGEF at an equal level and the DH-PD tandem over-expression were confirmed by subjecting the supernatant to Western blotting for FLAG epitope tag (data not shown). The supernatant was added to GST-RBD agarose beads (Millipore, Billerica MA) and affinity precipitated active RhoA•GTP was detected by Western blotting for RhoA using a mouse monoclonal antibody (Santa Cruz Biotechnology Inc., Santa Cruz CA). Detection and quantification of the signal was performed using the Odyssey system software (Li-Cor, Lincoln NE).
This work was supported by NIH Grant PO1 HL48807. We thank Natalya Olekhnovich for technical assistance and Dr. J. Otlewski (University of Wrocław, Poland) for discussions. This research benefited from access to the Southeast Collaboratory for High-Field Biomolecular NMR, a resource at the University of Georgia, funded by the National Institute of General Medical Sciences (GM66340) and the Georgia Research Alliance. We thank Dr. John Glushka and Dr. Yizhou Liu for assistance in setting up NMR experiments.
- Jaffe AB, Hall A: RHO GTPASES: Biochemistry and Biology. Annu Rev Cell Dev Biol 2005, 21: 247–269.View ArticlePubMedGoogle Scholar
- Raftopoulou M, Hall A: Cell migration: Rho GTPases lead the way. Dev Biol 2004, 265: 23–32.View ArticlePubMedGoogle Scholar
- Etienne-Manneville S, Hall A: Rho GTPases in cell biology. Nature 2002, 420: 629–635.View ArticlePubMedGoogle Scholar
- Kandpal RP: Rho GTPase activating proteins in cancer phenotypes. Curr Protein Pept Sci 2006, 7: 355–365.View ArticlePubMedGoogle Scholar
- Rossman KL, Der CJ, Sondek J: GEF means go: turning on RHO GTPases with guanine nucleotide-exchange factors. Nat Rev Mol Cell Biol 2005, 6: 167–180.View ArticlePubMedGoogle Scholar
- Whitehead IP, Campbell S, Rossman KL, Der CJ: Dbl family proteins. Biochim Biophys Acta 1997, 1332: F1–23.PubMedGoogle Scholar
- Erickson JW, Cerione RA: Structural elements, mechanism, and evolutionary convergence of Rho protein-guanine nucleotide exchange factor complexes. Biochemistry 2004, 43: 837–842.View ArticlePubMedGoogle Scholar
- Worthylake DK, Rossman KL, Sondek J: Crystal structure of Rac1 in complex with the guanine nucleotide exchange region of Tiam1. Nature 2000, 408: 682–688.View ArticlePubMedGoogle Scholar
- Aghazadeh B, Lowry WE, Huang XY, Rosen MK: Structural basis for relief of autoinhibition of the Dbl homology domain of proto-oncogene Vav by tyrosine phosphorylation. Cell 2000, 102: 625–633.View ArticlePubMedGoogle Scholar
- Mitin N, Betts L, Yohe ME, Der CJ, Sondek J, Rossman KL: Release of autoinhibition of ASEF by APC leads to CDC42 activation and tumor suppression. Nat Struct Mol Biol 2007, 14: 814–823.PubMed CentralView ArticlePubMedGoogle Scholar
- Murayama K, Shirouzu M, Kawasaki Y, Kato-Murayama M, Hanawa-Suetsugu K, Sakamoto A, Katsura Y, Suenaga A, Toyama M, Terada T, et al.: Crystal structure of the rac activator, Asef, reveals its autoinhibitory mechanism. J Biol Chem 2007, 282: 4238–4242.View ArticlePubMedGoogle Scholar
- Rojas RJ, Yohe ME, Gershburg S, Kawano T, Kozasa T, Sondek J: Galphaq directly activates p63RhoGEF and Trio via a conserved extension of the Dbl homology-associated pleckstrin homology domain. J Biol Chem 2007, 282: 29201–29210.PubMed CentralView ArticlePubMedGoogle Scholar
- Kozasa T, Jiang X, Hart MJ, Sternweis PM, Singer WD, Gilman AG, Bollag G, Sternweis PC: p115 RhoGef, a Gtpase activating protein for galpha12 and galpha13 [in Process Citation]. Science 1998, 280: 2109–2111.View ArticlePubMedGoogle Scholar
- Fukuhara S, Murga C, Zohar M, Igishi T, Gutkind JS: A novel PDZ domain containing guanine nucleotide exchange factor links heterotrimeric G proteins to Rho. J Biol Chem 1999, 274: 5868–5879.View ArticlePubMedGoogle Scholar
- Fukuhara S, Chikumi H, Gutkind JS: Leukemia-associated Rho guanine nucleotide exchange factor (LARG) links heterotrimeric G proteins of the G(12) family to Rho. FEBS Lett 2000, 485: 183–188.View ArticlePubMedGoogle Scholar
- Kourlas PJ, Strout MP, Becknell B, Veronese ML, Croce CM, Theil KS, Krahe R, Ruutu T, Knuutila S, Bloomfield CD, Caligiuri MA: Identification of a gene at 11q23 encoding a guanine nucleotide exchange factor: evidence for its fusion with MLL in acute myeloid leukemia. Proc Natl Acad Sci USA 2000, 97: 2145–2150.PubMed CentralView ArticlePubMedGoogle Scholar
- Chikumi H, Barac A, Behbahani B, Gao Y, Teramoto H, Zheng Y, Gutkind JS: Homo- and hetero-oligomerization of PDZ-RhoGEF, LARG and p115RhoGEF by their C-terminal region regulates their in vivo Rho GEF activity and transforming potential. Oncogene 2004, 23: 233–240.View ArticlePubMedGoogle Scholar
- Longenecker KL, Lewis ME, Chikumi H, Gutkind JS, Derewenda ZS: Structure of the RGS-like domain from PDZ-RhoGEF: linking heterotrimeric g protein-coupled signaling to Rho GTPases. Structure (Camb) 2001, 9: 559–569.View ArticleGoogle Scholar
- Chen Z, Wells CD, Sternweis PC, Sprang SR: Structure of the rgRGS domain of p115RhoGEF. Nat Struct Biol 2001, 8: 805–809.View ArticlePubMedGoogle Scholar
- Chen Z, Singer WD, Sternweis PC, Sprang SR: Structure of the p115RhoGEF rgRGS domain-Galpha13/i1 chimera complex suggests convergent evolution of a GTPase activator. Nat Struct Mol Biol 2005, 12: 191–197.View ArticlePubMedGoogle Scholar
- Kreutz B, Hajicek N, Yau DM, Nakamura S, Kozasa T: Distinct regions of Galpha13 participate in its regulatory interactions with RGS homology domain-containing RhoGEFs. Cell Signal 2007, 19: 1681–1689.View ArticlePubMedGoogle Scholar
- Suzuki N, Nakamura S, Mano H, Kozasa T: Galpha 12 activates Rho GTPase through tyrosine-phosphorylated leukemia-associated RhoGEF. Proc Natl Acad Sci USA 2003, 100: 733–738.PubMed CentralView ArticlePubMedGoogle Scholar
- Sternweis PC, Carter AM, Chen Z, Danesh SM, Hsiung YF, Singer WD: Regulation of Rho guanine nucleotide exchange factors by G proteins. Adv Protein Chem 2007, 74: 189–228.View ArticlePubMedGoogle Scholar
- Jemth P, Gianni S: PDZ domains: folding and binding. Biochemistry 2007, 46: 8701–8708.View ArticlePubMedGoogle Scholar
- Nourry C, Grant SG, Borg JP: PDZ domain proteins: plug and play! Sci STKE 2003, 2003: RE7.PubMedGoogle Scholar
- Hung AY, Sheng M: PDZ domains: structural modules for protein complex assembly. J Biol Chem 2002, 277: 5699–5702.View ArticlePubMedGoogle Scholar
- Swiercz JM, Kuner R, Behrens J, Offermanns S: Plexin-B1 Directly Interacts with PDZ-RhoGEF/LARG to Regulate RhoA and Growth Cone Morphology. Neuron 2002, 35: 51–63.View ArticlePubMedGoogle Scholar
- Aurandt J, Vikis HG, Gutkind JS, Ahn N, Guan KL: The semaphorin receptor plexin-B1 signals through a direct interaction with the Rho-specific nucleotide exchange factor, LARG. Proc Natl Acad Sci USA 2002, 99: 12085–12090.PubMed CentralView ArticlePubMedGoogle Scholar
- Perrot V, Vazquez-Prado J, Gutkind JS: Plexin B regulates Rho through the guanine nucleotide exchange factors Leukemia-associated RhoGEF (LARG) and PDZ-RhoGEF. J Biol Chem 2002, 277: 43115–43120.View ArticlePubMedGoogle Scholar
- Yamada T, Ohoka Y, Kogo M, Inagaki S: Physical and functional interactions of the lysophosphatidic acid receptors with PDZ domain-containing Rho guanine nucleotide exchange factors (RhoGEFs). J Biol Chem 2005, 280: 19358–19363.View ArticlePubMedGoogle Scholar
- Longhurst DM, Watanabe M, Rothstein JD, Jackson M: Interaction of PDZRhoGEF with microtubule-associated protein 1 light chains: link between microtubules, actin cytoskeleton, and neuronal polarity. J Biol Chem 2006, 281: 12030–12040.View ArticlePubMedGoogle Scholar
- Bourguignon LY, Gilad E, Brightman A, Diedrich F, Singleton P: Hyaluronan-CD44 interaction with leukemia-associated RhoGEF and epidermal growth factor receptor promotes Rho/Ras co-activation, phospholipase C epsilon-Ca2+ signaling, and cytoskeleton modification in head and neck squamous cell carcinoma cells. J Biol Chem 2006, 281: 14026–14040.View ArticlePubMedGoogle Scholar
- Oleksy A, Opalinski L, Derewenda U, Derewenda ZS, Otlewski J: The molecular basis of RhoA specificity in the guanine nucleotide exchange factor PDZ-RhoGEF. J Biol Chem 2006, 281: 32891–32897.View ArticlePubMedGoogle Scholar
- Bi F, Debreceni B, Zhu K, Salani B, Eva A, Zheng Y: Autoinhibition mechanism of proto-Dbl. Mol Cell Biol 2001, 21: 1463–1474.PubMed CentralView ArticlePubMedGoogle Scholar
- Yohe ME, Rossman KL, Gardner OS, Karnoub AE, Snyder JT, Gershburg S, Graves LM, Der CJ, Sondek J: Auto-inhibition of the Dbl family protein Tim by an N-terminal helical motif. J Biol Chem 2007, 282: 13813–13823.View ArticlePubMedGoogle Scholar
- Li P, Martins IR, Amarasinghe GK, Rosen MK: Internal dynamics control activation and activity of the autoinhibited Vav DH domain. Nat Struct Mol Biol 2008, 15: 613–618.PubMed CentralView ArticlePubMedGoogle Scholar
- Derewenda U, Oleksy A, Stevenson AS, Korczynska J, Dauter Z, Somlyo AP, Otlewski J, Somlyo AV, Derewenda ZS: The crystal structure of RhoA in complex with the DH/PH fragment of PDZRhoGEF, an activator of the Ca(2+) sensitization pathway in smooth muscle. Structure (Camb) 2004, 12: 1955–1965.View ArticleGoogle Scholar
- Koradi R, Billeter M, Wuthrich K: MOLMOL: a program for display and analysis of macromolecular structures. J Mol Graph 1996, 14: 51–55.View ArticlePubMedGoogle Scholar
- Amarasinghe GK, Rosen MK: Acidic region tyrosines provide access points for allosteric activation of the autoinhibited Vav1 Dbl homology domain. Biochemistry 2005, 44: 15257–15268.View ArticlePubMedGoogle Scholar
- Lutz S, Shankaranarayanan A, Coco C, Ridilla M, Nance MR, Vettel C, Baltus D, Evelyn CR, Neubig RR, Wieland T, Tesmer JJ: Structure of Galphaq-p63RhoGEF-RhoA complex reveals a pathway for the activation of RhoA by GPCRs. Science 2007, 318: 1923–1927.View ArticlePubMedGoogle Scholar
- Wells CD, Liu MY, Jackson M, Gutowski S, Sternweis PM, Rothstein JD, Kozasa T, Sternweis PC: Mechanisms for reversible regulation between G13 and Rho exchange factors. J Biol Chem 2002, 277: 1174–1181.View ArticlePubMedGoogle Scholar
- Chen Z, Singer WD, Wells CD, Sprang SR, Sternweis PC: Mapping the Galpha13 binding interface of the rgRGS domain of p115RhoGEF. J Biol Chem 2003, 278: 9912–9919.View ArticlePubMedGoogle Scholar
- Bhattacharyya R, Wedegaertner PB: Galpha 13 requires palmitoylation for plasma membrane localization, Rho-dependent signaling, and promotion of p115-RhoGEF membrane binding. J Biol Chem 2000, 275: 14992–14999.View ArticlePubMedGoogle Scholar
- Brooun A, Foster SA, Chrencik JE, Chien EY, Kolatkar AR, Streiff M, Ramage P, Widmer H, Weckbecker G, Kuhn P: Remedial strategies in structural proteomics: expression, purification, and crystallization of the Vav1/Rac1 complex. Protein Expr Purif 2007, 53: 51–62.PubMed CentralView ArticlePubMedGoogle Scholar
- Ihara K, Muraguchi S, Kato M, Shimizu T, Shirakawa M, Kuroda S, Kaibuchi K, Hakoshima T: Crystal structure of human RhoA in a dominantly active form complexed with a GTP analogue. J Biol Chem 1998, 273: 9656–9666.View ArticlePubMedGoogle Scholar
- Kelly AE, Ou HD, Withers R, Dotsch V: Low-conductivity buffers for high-sensitivity NMR measurements. J Am Chem Soc 2002, 124: 12013–12019.View ArticlePubMedGoogle Scholar
- Kitazawa T, Kobayashi S, Horiuti K, Somlyo AV, Somlyo AP: Receptor-coupled, permeabilized smooth muscle. Role of the phosphatidylinositol cascade, G-proteins, and modulation of the contractile response to Ca2+. J Biol Chem 1989, 264: 5339–5342.PubMedGoogle Scholar
- Iizuka K, Ikebe M, Somlyo AV, Somlyo AP: Introduction of high molecular weight (IgG) proteins into receptor coupled, permeabilized smooth muscle. Cell Calcium 1994, 16: 431–445.View ArticlePubMedGoogle Scholar
- Ren XD, Kiosses WB, Schwartz MA: Regulation of the small GTP-binding protein Rho by cell adhesion and the cytoskeleton. Embo J 1999, 18: 578–585.PubMed CentralView ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.